Generic placeholder image

Current Cancer Therapy Reviews

Author(s): Amal A. Mohamed , Dina M. Abo-Elmatty , Omnia I ezzat , Ahmed A. Youssef , Eman T. Mehanna , Alshymaa A. Hassnine , Noha M. Mesbah, Salma Saed, Eman Al Sayed , Mahmoud Hamada , Afaf F. Khamis, Ayman Elshentenawy, Marwa S.E. Abd El-Raouf, Sherief Abd-Elsalam* and Amr M. Elsayed

DOI: 10.2174/1573394717666210427122703

DownloadDownload PDF Flyer Cite As
Expression of a Disintegrin and Metalloprotease 10 Gene Polymorphisms in a Cohort of Egyptian Patients with Hepatocellular Carcinoma

Page: [312 - 318] Pages: 7

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality. There is a need for a marker associated with HCC progression. A disintegrin and metalloprotease (ADAMs) family proteins have a lot of functions in cell adhesion, migration, proteolysis and signaling.

Aims: The aim of the study was to investigate the relation between ADAM 10 gene single nucleotide polymorphisms (SNPs) and HCC progression.

Methods: This study involved 201 cases divided: Group I (67 HCC patients), Group II (67 cirrhotic patients), Group III (67 control). Each group was subjected to laboratory investigations: (CBC, blood sugar, kidney and liver function, viral markers, alpha fetoprotein), imaging: (abdominal ultrasonography, and triphasic C.T) and ADAM 10 gene polymorphism (rs 653765, rs 383902) detection by real – time PCR.

Results: There was a statistically significant difference in the frequency and genotyping of ADAM10 SNPs in HCC patients in comparison to cirrhotic and control groups [the frequency of rs 653765 genotypes (p=0.015) and model (p=0.013)]; likewise, the frequency of rs 383902 genotypes (p<0.001) and model (p=0.001)). Also, there was a statistically significant association between different SNP rs 383902 genotype with CLIP stages (p=0.02) and with VISUM stages (p=0.035).

Conclusion: ADAM-10 is overexpressed in HCC patients and involved in HCC progress. These findings highlight that ADAM inhibitor may be used as therapeutic goals in the treatment of HCC.

Keywords: Hepatocellular carcinoma (HCC), adisintegrin and metalloprotease (ADAMs), liver cirrhosis, single nucleotide polymorphisms (SNP), HBV, HCV.

[1]
Forner A, Reig M, Varela M, et al. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Med Clín 2016; 146(511): e1-e22.
[2]
Mohamed AA, Ali-Eldin ZA, Elbedewy TA, El-Serafy M, Ali-Eldin FA, AbdelAziz H. MicroRNAs and clinical implications in hepatocellular carcinoma. World J Hepatol 2017; 9(23): 1001-7.
[http://dx.doi.org/10.4254/wjh.v9.i23.1001] [PMID: 28878865]
[3]
Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol 2016; 22(4): 1497-512.
[http://dx.doi.org/10.3748/wjg.v22.i4.1497] [PMID: 26819517]
[4]
Omar A, Abou-Alfa GK, Khairy A, Omar H. Risk factors for developing hepatocellular carcinoma in Egypt. Linchuang Zhongliuxue Zazhi 2013; 2(4): 43.
[PMID: 25841922]
[5]
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6(9): 674-87.
[http://dx.doi.org/10.1038/nrc1934] [PMID: 16929323]
[6]
Liu S, Zhang W, Liu K, Ji B, Wang G. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells. Mol Med Rep 2015; 11(1): 597-602.
[http://dx.doi.org/10.3892/mmr.2014.2652] [PMID: 25323956]
[7]
Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: Multidomain proteins with multiple functions. Genes Dev 2003; 17(1): 7-30.
[http://dx.doi.org/10.1101/gad.1039703] [PMID: 12514095]
[8]
Murphy G. The ADAMs: Signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008; 8(12): 929-41.
[http://dx.doi.org/10.1038/nrc2459] [PMID: 19005493]
[9]
Klein T, Bischoff R. Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: Biological function and structure. J Proteome Res 2011; 10(1): 17-33.
[http://dx.doi.org/10.1021/pr100556z] [PMID: 20849079]
[10]
Blobel CP. ADAMs: Key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6(1): 32-43.
[http://dx.doi.org/10.1038/nrm1548] [PMID: 15688065]
[11]
Duffy MJ, McKiernan E, O’Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009; 15(4): 1140-4.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1585] [PMID: 19228719]
[12]
Yuan S, Lei S, Wu S. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells. Oncol Rep 2013; 30(4): 1715-22.
[http://dx.doi.org/10.3892/or.2013.2650] [PMID: 23912592]
[13]
Turner SL, Blair-Zajdel ME, Bunning RA. ADAMs and ADAMTSs in cancer. Br J Biomed Sci 2009; 66(2): 117-28.
[http://dx.doi.org/10.1080/09674845.2009.11730257] [PMID: 19637655]
[14]
Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des 2009; 15(20): 2288-99.
[http://dx.doi.org/10.2174/138161209788682442] [PMID: 19601831]
[15]
Prinzen C, Müller U, Endres K, Fahrenholz F, Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 2005; 19(11): 1522-4.
[http://dx.doi.org/10.1096/fj.04-3619fje] [PMID: 15972296]
[16]
Mohamed AA, Elsaid OM, Amer EA, et al. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res 2017; 8(4): 343-9.
[http://dx.doi.org/10.1016/j.jare.2017.03.004] [PMID: 28417047]
[17]
Baghdady I. Study of the risk factors for hepatocellular carcinoma: Effect of their synergism. J Am Sci 2013; 9(4): 211-7.
[18]
Helal N, Ageez A, Hirzi H, Aboushousha T. Differential GLUT1 expression in hepatocellular carcinoma and peri-malignant chronic virus c hepatitis. Int J Recent Sci Res 2017; 7(12): 14743-50.
[19]
Zhang W, Liu S, Liu K, et al. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression. J Int Med Res 2014; 42(3): 611-8.
[http://dx.doi.org/10.1177/0300060513505500] [PMID: 24670536]
[20]
Liu Y, Zhang W, Liu S, Liu K, Ji B, Wang Y. miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma. Oncol Rep 2017; 37(3): 1857-64.
[http://dx.doi.org/10.3892/or.2017.5423] [PMID: 28184920]
[21]
Shiu J-S, Hsieh M-J, Chiou H-L, et al. Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics. Int J Med Sci 2018; 15(12): 1334-40.
[http://dx.doi.org/10.7150/ijms.27059] [PMID: 30275760]
[22]
Negm O, Abou Saif S, El Gharib M, Yousef M, Abd-Elsalam S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2017; 29(3): 317-21.
[http://dx.doi.org/10.1097/MEG.0000000000000790] [PMID: 27893491]
[23]
Watany M, Badawi R, Elkhalawany W, Abd-Elsalam S. Study of Dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J Clin Diagn Res 2017; 11(2): OC32-4.
[http://dx.doi.org/10.7860/JCDR/2017/23095.9450] [PMID: 28384913]
[24]
Abdelfattah AAM, Rizk F, Hawash N, Hanafy A, El-Kalla F, Abd-Elsalam S. Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver. Int J Hyperthermia 2018; 34(8): 1367-71.
[http://dx.doi.org/10.1080/02656736.2018.1424946] [PMID: 29308685]
[25]
El-Gebaly F, Abou-Saif S, Elkadeem M, et al. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in Egyptian patients. Curr Cancer Drug Targets 2019; 19(11): 896-905.
[http://dx.doi.org/10.2174/1568009619666190718141647] [PMID: 31538897]